Search results
Added:
1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3…
View more
Added:
1 year ago
In this short interview, Dr Mohammed El-Sheikh discusses the key findings and clinical relevance of his recently published article, “Associations of Obesity and Prognostic Nutritional Index on 1-Year Mortality in Patients with Acute Heart Failure.”
View more
Added:
1 year ago
In this short video, Dr Ovidiu Chioncel shares why acute heart failure remains a critical area of focus in cardiology, highlighting the urgent need for improved strategies in diagnosis and management.This conversation sets the stage for his upcoming Special Focus in Cardiac Failure Review (Impact Factor: 4.2) in 2026, which will explore this topic further.
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Giuseppe Rosano and Dr Stephen Greene discuss the implementation of guideline-directed medical therapy (GDMT) in heart failure and strategies to overcome clinical inertia.
View more
Added:
1 year ago
ESC HF 25 - VELOCITY shows bypassing an initiation dose of 2.5mg, and and beginning with 5mg vericiguat safe and tolerable in 9/10 patients with heart failure with ejection fraction <45%.Prof Stephen Greene (Duke Clinical Research Institute, US) discusses the findings from VELOCITY (NCT06195930; Bayer), a phase 2b open-label clinical study evaluating the tolerability and safety of an…
View more
Added:
1 year ago
ESC Congress 2024 — FINEARTS-HF shows finerenone reduces cardiovascular death and total of worsening heart failure (HF) events over median follow-up of 32 months.Host, Dr Harriette Van Spall (McMaster University, CA) is joined by Principal investigator, Dr Scott Solomon (Brigham And Women's Hospital & Harvard Medical School, US) to discuss findings from the landmark FINEARTS-HF trial (NCT04435626…
View more
Added:
1 month ago
Dr Stephen J Greene (Duke University School of Medicine, Durham, NC, US) joins us to discuss the practical realities of delivering guideline-directed medical therapy (GDMT) in heart failure, and how clinicians and programmes can move more patients towards near-optimal treatment despite the constraints of everyday practice.In this interview, Dr Greene addresses the persistent gap between what…
View more
ESC HF 25: SCD-PROTECT
Added:
1 year ago
Video
Added:
1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
1 year ago
ACC 2025 - In this highlights video, Dr Ambarish Pandey (University of Texas Southwestern Medical Center, Texas, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:STRIDESOULFRESH-UPFAIR-HF 2Recorded on-site at ACC in Chicago, 2025.Support: This is an independent interview produced by Radcliffe…
View more